104 related articles for article (PubMed ID: 25694314)
1. Randomized controlled trials 6: On contamination and estimating the actual treatment effect.
Parfrey PS
Methods Mol Biol; 2015; 1281():249-59. PubMed ID: 25694314
[TBL] [Abstract][Full Text] [Related]
2. Randomized Controlled Trials 7: On Contamination and Estimating the Actual Treatment Effect.
Parfrey PS
Methods Mol Biol; 2021; 2249():307-318. PubMed ID: 33871851
[TBL] [Abstract][Full Text] [Related]
3. Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.
Kubo Y; Sterling LR; Parfrey PS; Gill K; Mahaffey KW; Gioni I; Trotman ML; Dehmel B; Chertow GM
Pharm Stat; 2015; 14(3):242-51. PubMed ID: 25851955
[TBL] [Abstract][Full Text] [Related]
4. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias?
Rimawi M; Hilsenbeck SG
J Clin Oncol; 2012 Feb; 30(4):453-8. PubMed ID: 22215751
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity analysis for the estimation of rates of change with non-ignorable drop-out: an application to a randomized clinical trial of the vitamin D3.
Matsuyama Y
Stat Med; 2003 Mar; 22(5):811-27. PubMed ID: 12587107
[TBL] [Abstract][Full Text] [Related]
6. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
7. Evaluating and adjusting for premature censoring of progression-free survival.
Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
[TBL] [Abstract][Full Text] [Related]
8. A general statistical principle for changing a design any time during the course of a trial.
Müller HH; Schäfer H
Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
[TBL] [Abstract][Full Text] [Related]
9. Using the instrumental variables estimator to analyze noninferiority trials with noncompliance.
Kim MY
J Biopharm Stat; 2010 Jul; 20(4):745-58. PubMed ID: 20496203
[TBL] [Abstract][Full Text] [Related]
10. Adjusting for observational secondary treatments in estimating the effects of randomized treatments.
Zhang M; Wang Y
Biostatistics; 2013 Jul; 14(3):491-501. PubMed ID: 23349243
[TBL] [Abstract][Full Text] [Related]
11. Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits.
Chu H; Nie L; Cole SR
Stat Med; 2006 Aug; 25(15):2647-57. PubMed ID: 16456897
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of clinical trials.
Wassertheil-Smoller S; Kim MY
Semin Nucl Med; 2010 Sep; 40(5):357-63. PubMed ID: 20674595
[TBL] [Abstract][Full Text] [Related]
13. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
Kombrink K; Munk A; Friede T
Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
[TBL] [Abstract][Full Text] [Related]
14. Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.
Kurland BF; Heagerty PJ
Stat Med; 2004 Sep; 23(17):2673-95. PubMed ID: 15316952
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
Hernández AV; Eijkemans MJ; Steyerberg EW
Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
[TBL] [Abstract][Full Text] [Related]
16. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
Yoshida M; Matsuyama Y; Ohashi Y;
Clin Trials; 2007; 4(4):318-28. PubMed ID: 17848493
[TBL] [Abstract][Full Text] [Related]
17. Treatment switching in oncology trials and the acceptability of adjustment methods.
Latimer NR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):561-4. PubMed ID: 25893990
[TBL] [Abstract][Full Text] [Related]
18. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
19. The challenges of evaluating dose response in flexible-dose trials using marginal structural models.
Lipkovich I; Mallinckrodt CH; Faries DE
Pharm Stat; 2012; 11(6):485-93. PubMed ID: 23060290
[TBL] [Abstract][Full Text] [Related]
20. Revisiting sample size: are big trials the answer?
Lurati Buse GA; Botto F; Devereaux PJ
J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():75-9. PubMed ID: 22810453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
